Tirzepatide

Mechanism of action

Activation of GIPR and GLP-1R receptors: (1) enhancement of insulin secretion in a glucose-dependent manner; (2) reduction of glucagon secretion (especially under hyperglycemic conditions); (3) slowing of gastric emptying (more pronounced in the initial phases and during titration), with reduction of postprandial peaks; (4) central modulation of satiety and eating behavior through hypothalamic and brainstem circuits; (5) improvement of insulin sensitivity and reduction of energy intake, contributing to fat mass loss. Dual GIP/GLP-1 action may produce an efficacy profile on weight and glycemia superior to that of selective GLP-1 agonists in some clinical contexts, while sharing some of the gastrointestinal adverse effects.

Supported benefits

• Reduction of HbA1c and improvement of glycemic control in type 2 diabetes (strong)
• Clinically significant weight loss in people with obesity/overweight (in specific regulatory contexts) (strong)
• Reduction in systolic blood pressure and improvement in some cardiometabolic markers (e.g. triglycerides) as secondary effects (moderate)
• Improvement in markers of hepatic steatosis/NAFLD in sub-studies and exploratory analyses (emerging)
• Reduction in the risk of major cardiovascular events: evolving evidence (dedicated trials ongoing/partially reported depending on agencies and time period) (emerging)

Safety & side effects

• Gastrointestinal (very common): nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, reduced appetite.
• Injection site reactions (redness, itching, pain).
• Possible dehydration secondary to vomiting/diarrhea with risk of worsening kidney function (especially in vulnerable individuals).
• Hypoglycemia: more likely in combination with insulin or sulfonylureas; less common as monotherapy thanks to the glucose-dependent mechanism.
• Cholelithiasis/cholecystitis: generally increased risk with rapid weight loss and with incretin-based therapies.
• Pancreatitis: a rare event but reported with this class; requires clinical attention in the presence of persistent severe abdominal pain.
• Increased resting heart rate (observed with some incretin agonists; clinical significance varies).

FAQ

Is it a supplement or a “research” peptide?

It is a peptide drug developed and studied in controlled clinical trials. It is not a supplement. The use of products labeled “research” outside regulated channels carries high quality and safety risks.

Why does it cause weight loss?

It primarily reduces appetite and increases satiety through incretin signals and neuroendocrine circuits; it also slows gastric emptying and improves glycemic control, helping to reduce caloric intake.

What are the most common side effects?

Nausea, diarrhea, constipation, vomiting, and dyspepsia are the most frequent. They are generally more pronounced during dose escalation and may decrease over time, but tolerability is individual.

Is there a risk of hypoglycemia?

On its own, it tends to have a lower risk because it stimulates insulin in a glucose-dependent manner. The risk increases if combined with insulin or sulfonylureas.

Does it affect the absorption of other drugs?

It may affect it indirectly because it slows gastric emptying, altering the absorption rate of some oral medications. For therapies with a narrow therapeutic window, clinical monitoring is advisable.

Is it true that it can increase the risk of gallbladder problems?

Rapid weight loss and some incretin-based therapies are associated with an increased risk of gallstones/cholecystitis in some individuals. The absolute risk varies and should be assessed clinically.